Animal-derived collagen
This document is technical information about materials. It does not recommend any procedure or product.
In brief
Collagen extracted from animal tissue, most often bovine, porcine or marine, and processed for use in dressings, scaffolds and injectable products. It is the long-established source of collagen biomaterials and the comparator against which recombinant production is presented in the literature.
Regulatory identity by market
COS cosmetic · MD medical device · RX drug · — not established in public sources
Identity & physical properties
| Synonyms | Animal-derived collagen, Bovine collagen, Porcine collagen, Marine collagen, Atelocollagen |
|---|---|
| Family | ECM structural protein — animal-derived |
| Morphology | Supplied as dressings, sponges, scaffolds and injectable preparations depending on processing |
| Molecular weight | Depends on extraction and processing. Telopeptide removal is described in the literature as a step aimed at reducing immunogenicity |
Mechanism
This material supplies extracellular matrix protein rather than provoking the host to build it. Reviews describe types I and III as the abundant dermal collagens and the basis for most collagen biomaterials in skin applications.
Evidence
| PMID | Study type | Summary |
|---|---|---|
| 31261996 | review | Review of collagen sources for skin wound-healing biomaterials, noting that most collagen in use is animal-derived |
| 40720447 | review | Review of collagen-based products across wound dressings, skin substitutes, scaffolds, topicals and supplements |
| 40852182 | in vivo | Filler development study describing disease-risk concerns attached to traditional animal-derived collagen as the motivation for a recombinant alternative |
Regulatory identity — detail
| Market | Classification | Note | Basis |
|---|---|---|---|
| KR | unclassified | Not established from public sources as of the revision date below. Classification depends on the presentation and claim rather than on the protein itself, and animal-tissue sourcing may bring additional requirements. | — |
| EU | unclassified | Not established from public sources as of the revision date below. | — |
| US | medical-device | Animal-derived collagen dermal implants hold FDA premarket approval under PMA P800022, listed with the generic name 'implant, dermal, for aesthetic use'. The earliest approval found is dated 1981, the earliest record listed under that generic name. | Legal text |
| JP | unclassified | Not established from public sources as of the revision date below. | — |
| CN | unclassified | Not established from public sources as of the revision date below. | — |
| VN | unclassified | Not established from public sources as of the revision date below. | — |
Limitations & open questions
Source species, extraction method and degree of processing differ widely and change what the finished material is, so a result reported for one preparation does not describe the category. The disease-risk and immunogenicity concerns associated with animal tissue are discussed in the literature cited here as a motivation for recombinant alternatives; this page reports that those concerns are raised, not that a specific risk has been quantified. The evidence cited is review-level apart from one preclinical study.
All statements on this page are drawn from the cited literature. Where a market’s regulatory classification could not be established from public sources, it is marked as not established rather than inferred.
Why this page exists alongside the recombinant entry
Most collagen used in biomaterials is extracted from animals. Recombinant production is a newer route presented in the literature specifically as an answer to the questions that extraction raises. Holding both pages open makes it possible to see which claims are about collagen and which are about where the collagen came from.
Processing is part of the material
Telopeptide removal, crosslinking and sterilisation each change the finished product. Two preparations sharing the label “bovine collagen” can differ enough that findings do not transfer between them. When a source-based argument is made, the processing route is the variable that decides whether it holds.